Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study
Academic Article
Publication Date:
2014
Short description:
Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study / Felker, G.M., Teerlink, J.R., Butler, J., Hernandez, A.F., Miller, A.B., Cotter, G., Davison, B.A., Filippatos, G., Greenberg, B.H., Ponikowski, P., Voors, A.A., Hua, T.A., Severin, T.M., Unemori, E., Metra, M.. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 1558-3597. - 64:15(2014), pp. 1591-1598. [10.1016/j.jacc.2014.05.071]
abstract:
Little is known about mode of death after acute heart failure (AHF) hospitalization. In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days in selected patients with AHF.
Iris type:
1.1 Articolo in rivista
Keywords:
cause of death; heart failure; relaxin; sudden cardiac death; Acute Disease; Aged; Cause of Death; Death; Sudden; Cardiac; Dose-Response Relationship; Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Injections; Intravenous; Male; Prospective Studies; Recombinant Proteins; Relaxin; Survival Rate; Treatment Outcome
List of contributors:
Felker, G. Michael; Teerlink, John R; Butler, Javed; Hernandez, Adrian F; Miller, Alan B; Cotter, Gad; Davison, Beth A; Filippatos, Gerasimos; Greenberg, Barry H; Ponikowski, Piotr; Voors, Adriaan A; Hua, Tsushung A; Severin, Thomas M; Unemori, Elaine; Metra, Marco
Published in: